French Regulators Clear Amicus-BioMarin Merger; Deal Set to Close April 27
FOLD has more than doubled off its 52-week low of $5.51.
Summary
Amicus Therapeutics has secured French foreign investment clearance for its merger with BioMarin. This crucial regulatory approval was the final condition for the merger agreement, aside from standard closing-time conditions. This development builds on the information from the company's recent 10-K filing (2026-02-20), which confirmed the BioMarin acquisition was progressing and had received HSR clearance. The French FDI clearance represents a new, specific, and final regulatory hurdle overcome. The receipt of this clearance significantly de-risks the transaction, providing certainty that the merger is on track. The announcement of an expected closing date of April 27, 2026, gives investors a clear timeline for the completion of this material corporate event. The market will now anticipate the official closing of the merger on the stated date.
At the time of this announcement, FOLD was trading at $14.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.